

Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Authors: ¹ Yuqin Song, ² Qingyuan Zhang, ³ Huilai Zhang, ⁴ Christopher R. Flowers, ⁵ Pier Luigi Zinzani, ⁶ Jiří Mayer, ⁷ Fontanet Bijou, ⁸ Ana C. de Oliveira, ⁹ Michele Merli, ¹⁰ Sarit E Assouline, ¹¹ Rebecca Auer, ¹² Pil Kim, ¹³ Adam Greenbaum, ¹³ Sha Huang, ¹⁴ Richard Delarue, ¹⁵ Judith Trotman.

Affiliations: ¹ Peking University Cancer Hospital and Institute, Beijing, China, ² Department of Medical Oncology, University Cancer Hospital, Harbin Medical University, Harbin, China, ³ Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy; Tianjin's Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China, ⁴ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁵ Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy, ⁶ Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic, ⁷ Institut Bergonié, Bordeaux, France, ⁸ Institut Català d'Oncologia (ICO) - Hospital Duran i Reynals, Barcelona, Spain, ⁹ Department of Medicine and Surgery, Hematology, ASST Sette Laghi, Varese, Italy, ¹⁰ Division of Hematology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ¹¹ St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, ¹² BeiGene USA, Inc, San Mateo, CA, USA, ¹³ BeiGene (Shanghai) Co, Ltd, Shanghai, China, ¹⁴ BeiGene International GmbH, Basel, Switzerland, ¹⁵ Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.

ABSTRACT

Objective: In an early-phase study, the combination of zanubrutinib plus obinutuzumab was well tolerated and associated with an early signal of efficacy in patients with follicular lymphoma (FL) (Tam et al. *Blood Adv.* 2020). ROSEWOOD (NCT03332017) is a phase 2, randomized study designed to assess the efficacy and safety of zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory (R/R) FL. Here we present an updated analysis with a median follow-up of 20.2 months.

Methods: Patients with R/R FL (grade 1-3A) who received ≥ 2 lines of therapy, including an anti-CD20 antibody and an alkylating agent, were randomized 2:1 to receive zanubrutinib plus obinutuzumab or obinutuzumab monotherapy. Zanubrutinib was given at 160 mg twice daily until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) by independent central review. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Time to next treatment (TTNT) was also assessed.

Results: A total of 217 patients were randomized to receive zanubrutinib plus obinutuzumab (n=145) or obinutuzumab (n=72). Median age was 64 years. Of the 217 patients, 114 (52.5%) had a high FL International Prognostic Index score at screening, and 123 patients (56.7%) had a high tumor burden according to Groupe d'Etude des Lymphomes Folliculaires criteria. The median number of prior lines of therapy was 3 (range, 2-11). A total of 114 patients (52.5%) were refractory to rituximab; 214 patients (98.6%) received prior immunochemotherapy. Prior anticancer drugs included anthracyclines (80.6%), cyclophosphamide (94.0%), and bendamustine (54.8%). The ORR was 69.0% (zanubrutinib plus obinutuzumab) vs 45.8% (obinutuzumab) ($P=.0012$). The complete response rate was 39.3% (zanubrutinib plus obinutuzumab) vs 19.4% (obinutuzumab) ($P=.0035$); the 18-month DOR rate was 69.3% (zanubrutinib plus obinutuzumab) vs 41.9% (obinutuzumab); and median PFS was 28.0 months

(zanubrutinib plus obinutuzumab) vs 10.4 months (obinutuzumab) (hazard ratio [HR], 0.50; 95% CI, 0.33-0.75; $P=.0007$). Median TTNT was not estimable for zanubrutinib plus obinutuzumab and 12.2 months for obinutuzumab (HR, 0.34; 95% CI, 0.22-0.52; $P<.0001$). The estimated 24-month OS rate was 77.3% (zanubrutinib plus obinutuzumab) vs 71.4% (obinutuzumab). The median OS was not reached in the zanubrutinib plus obinutuzumab arm and was 34.6 months in the obinutuzumab arm (HR, 0.62; 95% CI, 0.35-1.07; $P=.0845$). Nonhematologic treatment-emergent adverse events of any grade that occurred more frequently with zanubrutinib plus obinutuzumab vs obinutuzumab (>5% difference) were petechiae (6.3% vs 0%) and herpes zoster infection (6.3% vs 0%); in contrast, pyrexia (13.3% vs 19.7%) and infusion-related reaction (2.8% vs 9.9%) occurred more frequently in patients receiving obinutuzumab monotherapy. When adjusted for duration of treatment exposure, incidence rates of infection and cytopenia were similar, and the incidence rate of hemorrhage (any grade) was 2.4 (zanubrutinib plus obinutuzumab) vs 1.3 (obinutuzumab) persons per 100 person-months. Two patients in each treatment group reported major hemorrhage. Incidence rates of atrial fibrillation and hypertension were low and similar in both treatment arms.

Conclusion: Zanubrutinib plus obinutuzumab demonstrated meaningful activity and a manageable safety profile in patients with heavily pretreated R/R FL, representing a potential novel combination therapy.